Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Daclizumab HYP Monotherapy in Multiple Sclerosis (Post-205MS301)
2012-003176-39Phase 3Completed
- Sponsor
- Biogen
- Start
- Dec 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of daclizumab in multiple sclerosis (MS), sponsored by Biogen. Started Dec 2012; status: completed.
02
Drugs
daclizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-003176-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003176-39.